By Danny Sullivan – Longevity.Technology
Sam Altman revealed as mystery investor behind longevity biotech that aims to increase healthy human lifespan by 10 years.
Sam Altman, the American entrepreneur, investor and CEO of artificial intelligence giant OpenAI invested $180 million in longevity biotech startup Retro Bio in 2021. The revelation, made in an interview with MIT Technology Review, solves the mystery of who backed the company, which emerged last year with programs in cellular reprogramming, autophagy and plasma-inspired therapeutics.
